Issue of Equity

RNS Number : 7443D

Tissue Regenix Group PLC

02 February 2018

 

Tissue Regenix Group Plc

Issue of equity and total voting rights

Leeds, 02 February 2018 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Company"), the regenerative medical devices company, announces that it has today issued and allotted 658,081 ordinary shares of 0.5p each in the Company, following an exercise of options which were granted in respect of the 2015, 2016 and 2017 DAB awards.

The 658,081 new ordinary shares will rank pari passu with the existing ordinary shares and application has been made for these new ordinary shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00a.m. on Wednesday 7 February 2018.

Total Voting Rights

Following the issue of the 658,081 new ordinary shares, the Company will have a total of 1,171,649,005 ordinary shares of 0.5p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For more Information:

Tissue Regenix Group plc Steve Couldwell                              CEO Caitlin Pearson                                Head of Communications	Tel: [phone]
Jefferies International Ltd Simon Hardy / Chris Binks	Tel:  [phone]
FTI Consulting Brett Pollard/ Mo Noonan / Rob Winder	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

END

 

 

MSCQLLBBVLFLBBB